Cargando…

Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies

INTRODUCTION: Taletrectinib (AB-106/DS-6051b) is an oral, potent selective ROS1 and pan-NTRK tyrosine kinase inhibitor (TKI). Preclinically, taletrectinib has activity against ROS1 G2032R solvent-front mutation. METHODS: Patients with ROS1+ NSCLC enrolled into two phase 1 studies conducted in United...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ou, Sai-Hong Ignatius, Fujiwara, Yutaka, Shaw, Alice T., Yamamoto, Noboru, Nakagawa, Kazuhiko, Fan, Frank, Hao, Yuki, Gao, Yanfei, Jänne, Pasi A., Seto, Takashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474193/ https://www.ncbi.nlm.nih.gov/pubmed/34589973 http://dx.doi.org/10.1016/j.jtocrr.2020.100108

Ejemplares similares

Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study
por: Fujiwara, Yutaka, et al.
Publicado: (2018)

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
por: Katayama, Ryohei, et al.
Publicado: (2019)

Engineering Bacillus subtilis ATCC 6051a for the production of recombinant catalases
por: Ji, Minghua, et al.
Publicado: (2021)

A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

Multigene disruption in undomesticated Bacillus subtilis ATCC 6051a using the CRISPR/Cas9 system
por: Zhang, Kang, et al.
Publicado: (2016)

The diagnostic and prognostic values of Ki-67/MIB-1 expression in thyroid cancer: a meta-analysis with 6,051 cases
por: Pan, Deng-hua, et al.
Publicado: (2017)

Optimization of Effective Minerals on Riboflavin Production by Bacillus subtilis subsp. subtilis ATCC 6051 Using Statistical Designs
por: Oraei, Marjan, et al.
Publicado: (2018)

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
por: Drilon, Alexander, et al.
Publicado: (2022)

Efficient production of extracellular pullulanase in Bacillus subtilis ATCC6051 using the host strain construction and promoter optimization expression system
por: Liu, Xin, et al.
Publicado: (2018)

AB106. Role of Schwann cells in the regeneration of penile and peripheral nerves
por: Lin, Guiting, et al.
Publicado: (2015)

The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?
por: Brazel, Danielle, et al.
Publicado: (2023)

Complete Genome Sequence of Bacillus subtilis Strain ATCC 6051a, a Potential Host for High-Level Secretion of Industrial Enzymes
por: Jeong, Haeyoung, et al.
Publicado: (2015)

Devil in the detail: MET overexpression fails as surrogate marker for MET exon 14 splice site mutations in NSCLC
por: Strickland, Matthew R., et al.
Publicado: (2020)

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report
por: Thummalapalli, Rohit, et al.
Publicado: (2023)

Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
por: Frampton, James E.
Publicado: (2021)

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report
por: Takakura, Toshiaki, et al.
Publicado: (2023)

Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC
por: Wu, Yi-Long, et al.
Publicado: (2022)

Clinical and economic impact of ‘ROS1-testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in Spain
por: Rojo, Federico, et al.
Publicado: (2022)

Correction to: Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
por: Frampton, James E.
Publicado: (2021)

MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC
por: Tyler, Logan C., et al.
Publicado: (2022)

Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report
por: Begum, Parvin, et al.
Publicado: (2022)

Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement
por: Zhang, Limin, et al.
Publicado: (2016)

Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
por: Facchinetti, Francesco, et al.
Publicado: (2019)

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
por: Krawczyk, Paweł, et al.
Publicado: (2021)

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
por: Passiglia, Francesco, et al.
Publicado: (2016)

Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC
por: Keegan, Alissa, et al.
Publicado: (2020)

AB106. Association of alcohol consumption with lower urinary tract symptoms in a Chinese male population survey
por: Lu, Zheng, et al.
Publicado: (2014)

Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC
por: Cao, Hongxin, et al.
Publicado: (2016)

Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC
por: Lara, Matthew S., et al.
Publicado: (2022)

Identification of Flavonoids as Putative ROS-1 Kinase Inhibitors Using Pharmacophore Modeling for NSCLC Therapeutics
por: Parate, Shraddha, et al.
Publicado: (2021)

Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib
por: Facchinetti, Francesco, et al.
Publicado: (2021)

Unusual Resistance Mechanisms in a Case of ROS1-Rearranged NSCLC: A Case Report
por: Batra, Ullas, et al.
Publicado: (2022)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

EZH2 inhibition activates dsRNA-interferon axis stress and promotes response to PD-1 checkpoint blockade in NSCLC
por: Qiu, Fengqi, et al.
Publicado: (2022)

EF24 exerts cytotoxicity against NSCLC via inducing ROS accumulation
por: Chang, Minghui, et al.
Publicado: (2021)

Addendum to proposal P 106: consideration on the time scale for P106
por: CERN. Geneva. Intersecting Storage-Rings Committee
Publicado: (1980)

Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution
por: Schneider, Jaime L., et al.
Publicado: (2023)

Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

FreeSWITCH 106
por: Minessale, Anthony, et al.
Publicado: (2010)

S106. Submission Withdrawn
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l11scgps5r92ng6qbci4etmn6b